Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00333255 |
Recruitment Status :
Completed
First Posted : June 2, 2006
Last Update Posted : July 8, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cataract | Drug: Nepafenac Ophthalmic Suspension, 0.1% | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 267 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatment of Ocular Inflammation Associated With Cataract Surgery |
Study Start Date : | September 2005 |
Actual Primary Completion Date : | March 2006 |

- Percentage of patients who are a clinical success at Day 14 postoperative visit (where a "clinical success" is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).
- Percentage of patients who are clinically cured, clinical successes, treatment failure, clinically significant inflammation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 10 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- planned cataract extraction with posterior chamber intraocular lens implantation
Exclusion Criteria:
- Under 10

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00333255
United States, Texas | |
Lehmann Eye Center | |
Nacogdoches, Texas, United States, 76134 |
Study Director: | Andrew Maxwell | Study Director |
ClinicalTrials.gov Identifier: | NCT00333255 |
Other Study ID Numbers: |
C-04-41 |
First Posted: | June 2, 2006 Key Record Dates |
Last Update Posted: | July 8, 2009 |
Last Verified: | July 2009 |
Cataract Inflammation Pathologic Processes Lens Diseases Eye Diseases Nepafenac Anti-Inflammatory Agents, Non-Steroidal |
Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents |